REGN Q1 2022 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.0B+17.3% YoY

Gross Profit

$2.5B83.8% margin

Operating Income

$1.3B43.4% margin

Net Income

$974M32.8% margin

EPS (Diluted)

$8.61

QoQ Revenue Growth

-40.1%

Cash Flow

Operating Cash Flow

$2.1B

Free Cash Flow

$2.0B

Stock-Based Comp.

$167M

Balance Sheet

Total Assets

$26.3B

Total Liabilities

$6.4B

Stockholders' Equity

$19.9B

Cash & Equivalents

$3.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.0B	$2.5B	+17.3%
Gross Profit	$2.5B	$2.2B	+15.4%
Operating Income	$1.3B	$1.1B	+15.6%
Net Income	$974M	$1.1B	-12.7%

Revenue Segments

Product

$1.6B55%

Collaboration Revenue

$1.2B42%

Product and Service, Other

$94M3%